Is the Options Market Predicting a Spike in Prestige Consumer Healthcare Stock?
Investors need to pay close attention to PBH stock based on the movements in the options market lately.
PBH - Prestige Consumer Healthcare Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$66.00
DETAILS
HIGH:
$66.00
LOW:
$66.00
MEDIAN:
$66.00
CONSENSUS:
$66.00
UPSIDE:
34.97%
Stock News
Prestige Consumer Healthcare Inc. Completes Acquisition of LaCorium Health, Prices $400 Million Senior Notes Offering, and Announces First Quarter Fiscal 2027 Earnings Results Date
TARRYTOWN, N.Y., July 06, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Prestige”) today announced that it has closed the previously announced acquisition of LaCorium Health (“LaCorium”), priced a private offering of $400 million in senior notes, and will report its first quarter fiscal 2027 results on August 6, 2026.
Alphabet Joined the Dow and Became a Top Holding in Berkshire Hathaway's Portfolio. But This Stock Could Be an Even Better Buy.
This under-the-radar healthcare stock just made its biggest acquisition ever -- and it could easily outperform many of Wall Street's favorite names.
Prestige Consumer Healthcare Inc. Announces Offering of $400 Million Senior Notes
TARRYTOWN, N.Y., June 30, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE: PBH) (the “Company”) announced today that its wholly-owned subsidiary, Prestige Brands, Inc. (“Prestige Brands”), intends to offer, subject to market and other conditions, up to $400 million in aggregate principal amount of new senior notes due 2034 (the “notes”) in a private offering. The notes will be senior unsecured obligations of Prestige Brands and will be guaranteed by the Company and certain of its domestic subsidiaries.
Prestige Consumer Healthcare Inc. (PBH) Clear Eyes® and Pillar5 Problems Drive Stock Lower, HBSS Investigating
SAN FRANCISCO, June 25, 2026 /PRNewswire/ -- Investors in Prestige Consumer Healthcare (NYSE: PBH) saw the price of their shares fall over 11% on May 14, 2026 after the company revealed significant revenue declines and production problems driving the company's disappointing Q4 2026 financial results. The surprise developments have prompted national shareholder rights firm Hagens Berman to open an investigation into whether, before May 14, Prestige was sufficiently transparent regarding its ability to remediate supply chain constraints and, if not, whether the company violated the federal securities laws.
Prestige Consumer Healthcare Inc. (PBH) Clear Eyes® and Pillar5 Problems Drive Stock Lower, Hagens Berman Investigating
SAN FRANCISCO, June 23, 2026 (GLOBE NEWSWIRE) -- Investors in Prestige Consumer Healthcare (NYSE: PBH) saw the price of their shares fall over 11% on May 14, 2026 after the company revealed significant revenue declines and production problems driving the company's disappointing Q4 2026 financial results. The surprise developments have prompted national shareholder rights firm Hagens Berman to open an investigation into whether, before May 14, Prestige was sufficiently transparent regarding its ability to remediate supply chain constraints and, if not, whether the company violated the federal securities laws.
Prestige Consumer Healthcare Inc Completes Acquisition of Breathe Right®
TARRYTOWN, N.Y., June 15, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Prestige”) today announced that it has closed the previously announced acquisition of the Breathe Right® brand and certain other brands.
PBH Investors Have Opportunity to Join Prestige Consumer Healthcare Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. ("Prestige" or "the Company") (NYSE: PBH) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prestige Consumer Healthcare Inc. - PBH
NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. ("Prestige" or the "Company") (NYSE: PBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape
Amylyx Pharmaceuticals NASDAQ: AMLX Co-Chief Executive Officer Justin Klee said the company is preparing for a key Phase 3 readout for avexitide, its lead program for post-bariatric hypoglycemia, during an appearance at the Goldman Sachs Global Healthcare Conference.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prestige Consumer Healthcare Inc. - PBH
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. (“Prestige” or the “Company”) (NYSE: PBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
PBH Investors Have Opportunity to Join Prestige Consumer Healthcare Inc. Fraud Investigation with the Schall Law Firm
PBH Investors Have Opportunity to Join Prestige Consumer Healthcare Inc. Fraud Investigation with the Schall Law Firm PR Newswi
PBH Investors Have Opportunity to Join Prestige Consumer Healthcare Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. ("Prestige" or "the Company") (NYSE: PBH) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
[url="]Amylyx Pharmaceuticals, Inc.[/url] (NASDAQ: AMLX) (âAmylyxâ or the âCompanyâ) today announced two poster presentations at the upcoming Endocrine
Prestige Consumer Healthcare Inc. to Participate in the Oppenheimer Annual Consumer Growth and E-Commerce Conference
TARRYTOWN, N.Y., June 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will participate in a fireside chat at the Oppenheimer 26th Annual Consumer Growth and E-Commerce Conference virtually on Monday, June 8, 2026 at 9:45 a.m. ET. A live webcast of this event will be available at www.prestigeconsumerhealthcare.com under the "Investors” section and the "Events and Presentations" tab, or by using the following link:
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prestige Consumer Healthcare Inc. - PBH
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. ("Prestige" or the "Company") (NYSE: PBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prestige Consumer Healthcare Inc. - PBH
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. (“Prestige” or the “Company”) (NYSE: PBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Is the Options Market Predicting a Spike in Prestige Consumer Stock?
Investors need to pay close attention to PBH stock based on the movements in the options market lately.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prestige Consumer Healthcare Inc. - PBH
NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. ("Prestige" or the "Company") (NYSE: PBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prestige Consumer Healthcare Inc. - PBH
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. (“Prestige” or the “Company”) (NYSE: PBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Price Targets
Prestige Consumer price target lowered to $66 from $70 at Jefferies
$66.00
(was $64.18)
Keith Devas
·
Jefferies
Prestige Consumer price target lowered to $71 from $75 at Jefferies
$71.00
(was $61.95)
Jefferies
Presitge Brands (PBH) PT Raised to $86 at Canaccord Genuity
$86.00
(was $74.58)
SUsan Anderson
·
Canaccord Genuity
DA Davidson Defending Presitge Brands (PBH), Uprades to Buy
$93.00
(was $68.12)
Linda Bolton Weiser
·
D.A. Davidson
Canaccord Genuity Initiates Coverage On Prestige Consumer with Buy Rating, Announces Price Target of $71
$71.00
(was $58.35)
Canaccord Genuity